KILITCH DRUGS (INDIA)
|
|
BOM : 524500     NSE : KILITCH     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
May 27,2022 |
Price(EOD): ₹ 158.15
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 254.62 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
KILITCH DRUGS (INDIA) | 3.4% | -14.1% | -14.8% |
SUN PHARMACEUTICAL INDUSTRIES | -1.9% | -0.2% | 29.4% |
DIVIS LABORATORIES | -9.8% | -22.2% | -15.5% |
DR REDDYS LABORATORIES | 2.8% | 7.7% | -17.4% |
CIPLA | -0.4% | -1.1% | 3.1% |
GLAND PHARMA | -2.5% | -7.7% | -13% |
PIRAMAL ENTERPRISES | -12.8% | -23.8% | 9.1% |
CADILA HEALTHCARE | 3.1% | 8.4% | -40.1% |
TORRENT PHARMACEUTICALS | 12.4% | 8.5% | 6.5% |
FUNDAMENTAL ANALYSIS OF KILITCH DRUGS (INDIA)
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF KILITCH DRUGS (INDIA)
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
66.73
P/E Calculated based on EPS of 2.37
[ Mar2021 - Consolidated Results ] 1.93
P/B Calculated based on Book Value of 81.82
[ Mar2021 - Consolidated Results ] 2.61
P/S Calculated based on Revenues of 97.558 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
556% 45% 85% |
SHARE PRICE MOMENTUM OF KILITCH DRUGS (INDIA)
KILITCH DRUGS (INDIA) vs SENSEX
DEBT OF KILITCH DRUGS (INDIA)
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.09 0.08 0.06 0.08 |
0.12 0.11 0.08 0.1 |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF KILITCH DRUGS (INDIA)
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF KILITCH DRUGS (INDIA)
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
46.08% -79.19% -45.49% -76.26% |
69.39% -74.78% -40.76% -71.92% |
QtrlyTrend |
-4 | |
Latest Qtr: Dec2021 | ||
Quarterly Result Analysis → |
KILITCH DRUGS (INDIA) related INDICES
You may also like the below Video Courses
FAQ about KILITCH DRUGS (INDIA)
Is KILITCH DRUGS (INDIA) good for long term investment?
As on May 27,2022, the Fundamentals of KILITCH DRUGS (INDIA) look Poor and hence it may not be good for long term investment ! See Financial Performance of KILITCH DRUGS (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is KILITCH DRUGS (INDIA) UnderValued or OverValued?
As on May 27,2022, KILITCH DRUGS (INDIA) is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of KILITCH DRUGS (INDIA) ?
As on May 27,2022, the Intrinsic Value of KILITCH DRUGS (INDIA) is Rs. 85.51 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 24.09
Fair Value [Median EV / Sales Model] : Rs. 109.23
Fair Value [Median Price / Sales Model] : Rs. 85.51
Median Fair Value of KILITCH DRUGS (INDIA) : Rs. 85.51
Is KILITCH DRUGS (INDIA) trading at a Premium or Discount?
As on May 27,2022, KILITCH DRUGS (INDIA) is trading at a Premium of 85% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
